Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:KMDA
- CUSIP: N/A
- Web: www.kamada.com
- Market Cap: $171.18 million
- Outstanding Shares: 37,400,000
- 50 Day Moving Avg: $4.49
- 200 Day Moving Avg: $6.19
- 52 Week Range: $3.75 - $8.61
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.75
- P/E Growth: 8.70
- Annual Revenue: $87.83 million
- Price / Sales: 2.02
- Book Value: $1.83 per share
- Price / Book: 2.60
- EBIDTA: $1.94 million
- Net Margins: -2.24%
- Return on Equity: -2.94%
- Return on Assets: -2.03%
- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 2.85%
- Quick Ratio: 1.95%
- Average Volume: 173,698 shs.
- Beta: 1.04
- Short Ratio: 0.08
Frequently Asked Questions for Kamada (NASDAQ:KMDA)
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Tuesday, August, 1st. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.01. The firm earned $32.55 million during the quarter, compared to analyst estimates of $33.30 million. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The business's quarterly revenue was up 70.7% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. View Kamada's Earnings History.
When will Kamada make its next earnings announcement?
Where is Kamada's stock going? Where will Kamada's stock price be in 2017?
2 equities research analysts have issued 12-month target prices for Kamada's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Kamada's share price to reach $8.50 in the next twelve months. View Analyst Ratings for Kamada.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Mirna Therapeutics (SYBX), Strongbridge Biopharma PLC (SBBP), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Alimera Sciences (ALIM), Opiant Pharmaceuticals (OPNT), Cardiome Pharma Corporation (CRME), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS) and Ocera Therapeutics (OCRX).
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Leon Yehuda Recanati, Chairman of the Board
- Amir London, Chief Executive Officer
- Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
- David Tsur, Deputy Chairman of the Board
- Ruth Wolfson, Senior Vice President - Scientific Affairs
- Barak Bashari, Vice President - Operations
- Shani Dotan, Vice President - Human Resources
- Yael Brenner, Vice President - Quality
- Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
- Eran Schenker, Vice President - Medical Director
Who owns Kamada stock?
Kamada's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
BROSH CAPITAL PARTNERS L.P.
(6.20%), Paulson & CO. Inc. (2.17%), Vanguard Group Inc. (1.30%), Migdal Insurance & Financial Holdings Ltd. (1.27%), Nexthera Capital LP (0.83%) and Navellier & Associates Inc (0.14%). View Institutional Ownership Trends for Kamada.
Who sold Kamada stock? Who is selling Kamada stock?
Who bought Kamada stock? Who is buying Kamada stock?
Kamada's stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Paulson & CO. Inc., Navellier & Associates Inc, Vanguard Group Inc. and Edmond DE Rothschild Holding S.A.. View Insider Buying and Selling for Kamada.
How do I buy Kamada stock?
Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kamada's stock price today?
MarketBeat Community Rating for Kamada (NASDAQ KMDA)MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Kamada stock can currently be purchased for approximately $4.75.
Consensus Ratings for Kamada (NASDAQ:KMDA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$8.50 (78.95% upside)|
Analysts' Ratings History for Kamada (NASDAQ:KMDA)
(Data available from 9/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/2/2017||Jefferies Group LLC||Reiterated Rating||Buy||$9.00 -> $7.00||Low|
|2/7/2017||HC Wainwright||Set Price Target||Buy||$10.00||N/A|
Earnings History for Kamada (NASDAQ:KMDA)Earnings History by Quarter for Kamada (NASDAQ KMDA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|8/1/2017||6/30/2017||$0.12||$0.13||$33.30 million||$32.55 million||View||Listen|
|5/16/2017||3/31/2017||($0.03)||($0.11)||$20.82 million||$11.65 million||View||N/A|
|2/6/2017||12/31/2016||($0.04)||($0.05)||$27.74 million||$24.26 million||View||Listen|
|11/10/2016||9/30/2016||($0.04)||($0.03)||$20.32 million||$19.37 million||View||N/A|
|8/2/2016||Q216||($0.04)||($0.04)||$18.50 million||$19.10 million||View||N/A|
|5/9/2016||Q1 2016||($0.06)||($0.06)||$15.10 million||$14.80 million||View||N/A|
|2/2/2016||Q415||($0.09)||$0.03||$27.10 million||$25.90 million||View||N/A|
|11/10/2015||Q315||($0.04)||($0.13)||$18.67 million||$16.10 million||View||Listen|
|7/30/2015||Q215||($0.03)||($0.06)||$21.82 million||$19.20 million||View||Listen|
|5/12/2015||Q115||($0.05)||($0.15)||$16.12 million||$9.00 million||View||Listen|
|2/11/2015||Q4||$0.01||$0.05||$24.53 million||$25.79 million||View||N/A|
|11/12/2014||Q314||($0.04)||($0.09)||$19.00 million||$17.20 million||View||N/A|
|8/14/2014||Q214||($0.02)||($0.23)||$17.17 million||$15.80 million||View||N/A|
|5/8/2014||Q114||($0.03)||($0.09)||$15.97 million||$13.20 million||View||N/A|
|2/5/2014||Q413||$0.05||$0.04||$25.22 million||$24.40 million||View||N/A|
Earnings Estimates for Kamada (NASDAQ:KMDA)
2017 EPS Consensus Estimate: $0.17
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Kamada (NASDAQ:KMDA)
Latest Headlines for Kamada (NASDAQ:KMDA)
|Kamada Announces CFO Transition|
finance.yahoo.com - September 18 at 7:45 PM
|ETFs with exposure to Kamada Ltd. : September 14, 2017|
finance.yahoo.com - September 15 at 3:56 AM
|Kamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017|
finance.yahoo.com - September 14 at 6:57 AM
|Analyzing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)|
www.americanbankingnews.com - September 7 at 10:03 AM
|Kamada to Present Corporate Overview at Two Investor Conferences in September|
feeds.benzinga.com - September 7 at 8:20 AM
|Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action|
finance.yahoo.com - September 6 at 8:42 PM
|Kamada Ltd. (KMDA) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - September 2 at 11:50 PM
|Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares|
finance.yahoo.com - August 31 at 6:44 AM
|Kamada (KMDA) Says FDA Issued Letter Stating that it Continues to Have Concerns and Questions About Safety and Efficacy of Inhaled AAT|
www.streetinsider.com - August 29 at 5:59 AM
|FY2018 EPS Estimates for Kamada Ltd. Lowered by Jefferies Group (KMDA)|
www.americanbankingnews.com - August 28 at 9:04 AM
|Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection|
finance.yahoo.com - August 25 at 7:41 AM
|Reviewing Kamada (KMDA) & MediWound (MDWD)|
www.americanbankingnews.com - August 21 at 4:26 PM
|$24.84 Million in Sales Expected for Kamada Ltd. (KMDA) This Quarter|
www.americanbankingnews.com - August 18 at 3:32 PM
|Brokers Issue Forecasts for Kamada Ltd.'s FY2018 Earnings (KMDA)|
www.americanbankingnews.com - August 3 at 3:30 PM
|Jefferies Group LLC Reiterates Buy Rating for Kamada Ltd. (NASDAQ:KMDA)|
www.americanbankingnews.com - August 2 at 4:38 PM
|Kamada Ltd. to Post Q3 2017 Earnings of $0.02 Per Share, Jefferies Group Forecasts (NASDAQ:KMDA)|
www.americanbankingnews.com - August 2 at 7:02 AM
|Kamada Reports Financial Results for Second Quarter and First Six Months of 2017|
finance.yahoo.com - August 2 at 2:45 AM
|Kamada posts 2Q profit|
finance.yahoo.com - August 2 at 2:44 AM
|Kamada Ltd. (NASDAQ:KMDA) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS|
www.americanbankingnews.com - August 1 at 10:47 AM
|Kamada (KMDA) Prices 3.33M Public Offering at $4.50/Ordinary Share|
www.streetinsider.com - July 30 at 5:24 AM
|Kamada Announces Pricing of Public Offering of Ordinary Shares|
finance.yahoo.com - July 29 at 1:18 AM
|Zacks: Brokerages Expect Kamada Ltd. (KMDA) to Post $0.12 Earnings Per Share|
www.americanbankingnews.com - July 28 at 10:24 PM
|Kamada to Host Second Quarter 2017 Financial Results Conference Call on August 1|
finance.yahoo.com - July 28 at 1:34 AM
|Kamada Announces Proposed Public Offering of Ordinary Shares|
finance.yahoo.com - July 28 at 1:34 AM
|Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017|
finance.yahoo.com - July 28 at 1:34 AM
|Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease|
finance.yahoo.com - July 21 at 12:52 AM
|ETFs with exposure to Kamada Ltd. : July 7, 2017|
finance.yahoo.com - July 8 at 12:04 PM
|$32.90 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This Quarter|
www.americanbankingnews.com - July 6 at 10:08 AM
|Zacks: Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Earnings of $0.12 Per Share|
www.americanbankingnews.com - July 4 at 6:24 PM
|Kamada Withdraws Inhaled AAT Marketing Application in EU|
finance.yahoo.com - June 23 at 6:35 PM
|Kamada (KMDA) Withdrawal of European MAA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease|
www.streetinsider.com - June 23 at 7:34 AM
|Kamada Ltd. (KMDA) Is Sinking After European Application Withdrawn|
www.nasdaq.com - June 23 at 7:34 AM
|Kamada Ltd. (KMDA) Sank To Nearly A 5-Month Low|
www.rttnews.com - June 23 at 7:34 AM
|Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease|
finance.yahoo.com - June 22 at 12:44 PM
|ETFs with exposure to Kamada Ltd. : June 16, 2017|
finance.yahoo.com - June 16 at 7:04 PM
|Kamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017|
finance.yahoo.com - June 14 at 10:58 AM
|Kamada (KMDA) Receives Additional Milestone Payment Under GLASSIA Agreement with Shire|
www.streetinsider.com - June 13 at 8:36 AM
|Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire|
finance.yahoo.com - June 12 at 3:21 PM
|$32.90 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter|
www.americanbankingnews.com - June 10 at 8:22 AM
|$0.12 Earnings Per Share Expected for Kamada Ltd (KMDA) This Quarter|
www.americanbankingnews.com - June 8 at 4:30 PM
|Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease|
finance.yahoo.com - June 7 at 9:39 AM
|Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director|
finance.yahoo.com - June 5 at 9:58 AM
|Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference|
finance.yahoo.com - May 24 at 11:14 AM
|Kamada Ltd (KMDA) to Post Q2 2017 Earnings of $0.10 Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - May 19 at 7:16 AM
|Short Interest in Kamada Ltd (KMDA) Decreases By 9.0%|
www.americanbankingnews.com - May 18 at 4:22 PM
|Kamada Ltd (KMDA) Downgraded to "Strong Sell" at Zacks Investment Research|
www.americanbankingnews.com - May 18 at 12:30 PM
|FY2017 EPS Estimates for Kamada Ltd Reduced by Jefferies Group (KMDA)|
www.americanbankingnews.com - May 18 at 10:38 AM
|Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss|
finance.yahoo.com - May 17 at 6:10 PM
|Kamada Ltd (KMDA) Earns Buy Rating from Jefferies Group LLC|
www.americanbankingnews.com - May 17 at 11:34 AM
|Kamada Ltd (KMDA) Issues Earnings Results|
www.americanbankingnews.com - May 17 at 10:03 AM
Kamada (KMDA) Chart for Saturday, September, 23, 2017